

REGENERON PHARMACEUTICALS INC.

ISIN: US75886F1075 WKN: 75886F107 Asset Class: Stock

Company

2022/06/27 22:00:00

REGENERON

Price
602.40
USD

Difference  **-1.65%(-10.09)**



Contact Details

REGENERON
PHARMACEUTICALS INC.

Tel: 1-914-847-7000

--

Fax: -

777 Old Saw Mill River Road

Web:

<http://www.regeneron.com>

10591-6707 Tarrytown

E-mail: -

Company Profile

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as Velocimmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2021		2020		2019	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	14,014,900,000		9,779,100,000		7,689,100,000	
Common stock capital		100,000		100,000		100,000
Fixed assets	11,419,900,000		7,384,200,000		7,116,100,000	
Equity capital of a company		18,768,800,000		11,025,300,000		11,089,700,000
Cash and cash equivalents	2,885,600,000		2,193,700,000		1,617,800,000	
Accrued liabilities		0		0		0
Other assets	-		-		-	
Current liabilities		3,932,500,000		2,697,400,000		2,096,600,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		2,733,500,000		3,440,600,000		1,618,900,000
Different income		-		-		-
Other liabilities		753,500,000		744,900,000		905,000,000
Total assets	25,434,800,000	25,434,800,000	17,163,300,000	17,163,300,000	14,805,200,000	14,805,200,000

Balance notes

	2021	2020	2019
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	10,368	9,123	8,100
Equity ratio	73.79%	64.24%	74.90%
Debt-equity ratio	35.52%	55.67%	33.50%

Others

	2021	2020	2019
Tax Expense Rate	13.41%	7.80%	12.90%

REGENERON PHARMACEUTICALS INC.

ISIN: US75886F1075 WKN: 75886F107 Asset Class: Stock

Income statement

	2021	2020	2019
Turnover	16,071,700,000	8,497,100,000	7,863,400,000
Net income	8,075,300,000	3,513,200,000	2,115,800,000
EBIT	8,920,513,170	3,676,642,110	2,338,056,510
Operating income before taxes	9,325,800,000	3,810,400,000	2,429,100,000
Cash Flow	7,081,300,000	2,618,100,000	2,430,000,000
Net interest income	-57,300,000	-56,900,000	-30,200,000
Research and development expenses	2,621,900,000	2,499,100,000	2,826,300,000
Income taxes	1,250,500,000	297,200,000	313,300,000
Result from investments in subsidiaries, associates and other	-	-	-
Revenues per employee	1,473,704	885,475	922,930

Board of Directors

Members of Management Board

P. Vagelos	Chairman of Board of Directors
Bonnie Bassler	Member of Board of Directors
George Yancopoulos	Member of Board of Directors
Huda Zoghbi	Member of Board of Directors
Joseph Goldstein	Member of Board of Directors
Marc Tessier-Lavigne	Member of Board of Directors
Michael Brown	Member of Board of Directors
N. Coles	Member of Board of Directors
Arthur Ryan	Member of Board of Directors
Christine Poon	Member of Board of Directors
George Sing	Member of Board of Directors
Leonard S. Schleifer	Chairman of Managing Board
George D. Yancopoulos	Member of Executive Committee
Robert E. Landry	Member of Executive Committee